Answers are grounded in this paper and cite their sources.
Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-γ (IFN-γ), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to HLH therapy. This review will highlight the pathophysiology of primary HLH, the therapeutic rationale for use of IFN-γ-targeting therapy, and potential limitations to its broader use in the treatment of HLH.
No takes yet. Share an insight, caveat, or question.
Vallurupalli et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: